CVRX
CVRx, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.03
P/S
4.20
EV/EBITDA
-4.48
DCF Value
$-173.47
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.3%
Operating Margin
-90.5%
Net Margin
-94.1%
ROE
-99.3%
ROA
-50.9%
ROIC
-56.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $16.0M | $-11.9M | $-0.46 |
| FY 2025 | $56.7M | $-53.3M | $-2.04 |
| Q3 2025 | $14.7M | $-12.9M | $-0.49 |
| Q2 2025 | $13.6M | $-14.7M | $-0.57 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.12
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.